Your browser doesn't support javascript.
loading
SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys
Kevin O Saunders; Esther Lee; Robert Parks; David R Martinez; Dapeng Li; Haiyan Chen; Robert J Edwards; Sophie M. C. Gobeil; Maggie Barr; Katayoun Mansouri; S Munir Alam; Laura L Sutherland; Fangping Cai; Aja Sanzone; Madison Berry; Kartik Manne; Anyway B Kapingidza; Mihai Azoitei; Longping V Tse; Trevor D Scobey; Rachel Spreng; R. Wes Rountree; C Todd DeMarco; Thomas N Denny; Christopher W Woods; Elizabeth W Petzold; Thomas H Oguin III; Gregory D Sempowski; Matthew Gagne; Daniel C Douek; Mark A Tomai; Christopher B Fox; Robert Seder; Kevin Wiehe; Drew Weissman; Norbert Pardi; Priyamvada Acharya; Hanne Andersen; Mark G Lewis; Ian N Moore; David C Montefiori; Ralph S Baric; Barton F Haynes.
Affiliation
  • Kevin O Saunders; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University, Durham, NC 27710, USA; Departme
  • Esther Lee; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Robert Parks; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • David R Martinez; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
  • Dapeng Li; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Haiyan Chen; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Robert J Edwards; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Sophie M. C. Gobeil; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Maggie Barr; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Katayoun Mansouri; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • S Munir Alam; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Laura L Sutherland; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Fangping Cai; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Aja Sanzone; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Madison Berry; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Kartik Manne; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Anyway B Kapingidza; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Mihai Azoitei; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Longping V Tse; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
  • Trevor D Scobey; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
  • Rachel Spreng; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • R. Wes Rountree; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • C Todd DeMarco; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
  • Thomas N Denny; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
  • Christopher W Woods; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Elizabeth W Petzold; Center for Applied Genomics and Precision Medicine, Duke University Medical Center, Durham, NC 27710, USA
  • Thomas H Oguin III; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Gregory D Sempowski; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Matthew Gagne; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD 20892, USA
  • Daniel C Douek; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD 20892, USA
  • Mark A Tomai; Corporate Research Materials Lab, 3M Company, St. Paul, MN 55144, USA.
  • Christopher B Fox; Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Beth
  • Robert Seder; Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD 20892, USA
  • Kevin Wiehe; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
  • Drew Weissman; Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
  • Norbert Pardi; Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
  • Priyamvada Acharya; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University, Durham, NC 27710, USA
  • Hanne Andersen; BIOQUAL, Rockville, MD 20850, USA
  • Mark G Lewis; BIOQUAL, Rockville, MD 20850, USA
  • Ian N Moore; Infectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Beth
  • David C Montefiori; Department of Surgery, Duke University, Durham, NC 27710, USA
  • Ralph S Baric; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
  • Barton F Haynes; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC
Preprint in En | PREPRINT-BIORXIV | ID: ppbiorxiv-431492
ABSTRACT
Betacoronaviruses (betaCoVs) caused the severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) outbreaks, and now the SARS-CoV-2 pandemic. Vaccines that elicit protective immune responses against SARS-CoV-2 and betaCoVs circulating in animals have the potential to prevent future betaCoV pandemics. Here, we show that immunization of macaques with a multimeric SARS-CoV-2 receptor binding domain (RBD) nanoparticle adjuvanted with 3M-052-Alum elicited cross-neutralizing antibody responses against SARS-CoV-1, SARS-CoV-2, batCoVs and the UK B.1.1.7 SARS-CoV-2 mutant virus. Nanoparticle vaccination resulted in a SARS-CoV-2 reciprocal geometric mean neutralization titer of 47,216, and robust protection against SARS-CoV-2 in macaque upper and lower respiratory tracts. Importantly, nucleoside-modified mRNA encoding a stabilized transmembrane spike or monomeric RBD protein also induced SARS-CoV-1 and batCoV cross-neutralizing antibodies, albeit at lower titers. These results demonstrate current mRNA vaccines may provide some protection from future zoonotic betaCoV outbreaks, and provide a platform for further development of pan-betaCoV nanoparticle vaccines.
License
cc_no
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Type of study: Rct Language: En Year: 2021 Document type: Preprint
Fulltext
Add to My VHL
Print
XML
Search on Google
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Type of study: Rct Language: En Year: 2021 Document type: Preprint